{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:10:50Z","timestamp":1793250650046,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.kint.2020.12.013","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T02:49:34Z","timestamp":1608691774000},"page":"1088-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Empagliflozin restores chronic kidney disease\u2013induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction"],"prefix":"10.1016","volume":"99","author":[{"given":"Rio P.","family":"Juni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushd","family":"Al-Shama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik W.D.","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Vervloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etto C.","family":"Eringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Koolwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.M.","family":"van Hinsbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.12.013_bib1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1159\/000502874","article-title":"Association of chronic kidney disease with preserved ejection fraction heart failure is independent of baseline cardiac function","volume":"44","author":"Mavrakanas","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2020.12.013_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ejhf.461","article-title":"Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2020.12.013_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.445","article-title":"Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction","volume":"18","author":"Unger","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2020.12.013_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41598-018-37690-5","article-title":"Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212","volume":"9","author":"Sarkozy","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2020.12.013_bib5","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.jacc.2019.02.074","article-title":"Osteopontin promotes left ventricular diastolic dysfunction through a mitochondrial pathway","volume":"73","author":"Yousefi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2020.12.013_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000473868","article-title":"Heart failure with preserved and reduced ejection fraction in hemodialysis patients: prevalence, disease prediction and prognosis","volume":"42","author":"Antlanger","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2020.12.013_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jacc.2015.12.052","article-title":"Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis","volume":"67","author":"Hickson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2020.12.013_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"03","author":"Lund","year":"2017","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.kint.2020.12.013_bib9","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2020.12.013_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2020.12.013_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","article-title":"Evolving concepts in the pathogenesis of uraemic cardiomyopathy","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2020.12.013_bib12","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.12.013_bib13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2013121283","article-title":"The cardiovascular effect of the uremic solute indole-3 acetic acid","volume":"26","author":"Dou","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.12.013_bib14","doi-asserted-by":"crossref","first-page":"H1414","DOI":"10.1152\/ajpheart.00272.2018","article-title":"FGF23 impairs peripheral microvascular function in renal failure","volume":"315","author":"Verkaik","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kint.2020.12.013_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.kint.2020.12.013_bib16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2020.12.013_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.12.013_bib18","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.12.013_bib19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.12.013_bib20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.12.013_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.12.013_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.12.013_bib23","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.kint.2020.12.013_bib24","doi-asserted-by":"crossref","first-page":"41166","DOI":"10.1038\/srep41166","article-title":"Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart","volume":"7","author":"Van Steenbergen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2020.12.013_bib25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2020.12.013_bib26","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","article-title":"Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes","volume":"4","author":"Iborra-Egea","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.kint.2020.12.013_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kint.2020.12.013_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.kint.2020.12.013_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2020.12.013_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/377239a0","article-title":"Hypertension in mice lacking the gene for endothelial nitric oxide synthase","volume":"377","author":"Huang","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.kint.2020.12.013_bib31","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: from marvel to menace","volume":"113","author":"Forstermann","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2020.12.013_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antiox7010013","article-title":"Reactive oxygen species and mitochondrial dynamics: the yin and yang of mitochondrial dysfunction and cancer progression","volume":"7","author":"Jezek","year":"2018","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.kint.2020.12.013_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"10.1016\/j.kint.2020.12.013_bib34","doi-asserted-by":"crossref","first-page":"110642","DOI":"10.1016\/j.mce.2019.110642","article-title":"Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway","volume":"501","author":"Lu","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kint.2020.12.013_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.kint.2020.12.013_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nephro.2006.04.004","article-title":"New insights on inflammation in chronic kidney disease-genetic and non-genetic factors","volume":"2","author":"Stenvinkel","year":"2006","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.kint.2020.12.013_bib37","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"issue":"84","key":"10.1016\/j.kint.2020.12.013_bib38","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1046\/j.1523-1755.63.s84.41.x","article-title":"Oxidative consumption of nitric oxide: a potential mediator of uremic vascular disease","author":"Thuraisingham","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2020.12.013_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fphys.2015.00102","article-title":"Uremic myopathy: is oxidative stress implicated in muscle dysfunction in uremia?","volume":"6","author":"Kaltsatou","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.kint.2020.12.013_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12471-016-0810-1","article-title":"Understanding heart failure with preserved ejection fraction: where are we today?","volume":"24","author":"van Heerebeek","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.kint.2020.12.013_bib41","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1253\/circj.CJ-12-0664","article-title":"Cyclic GMP-dependent signaling in cardiac myocytes","volume":"76","author":"Takimoto","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.kint.2020.12.013_bib42","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCRESAHA.114.301286","article-title":"Gigantic business: titin properties and function through thick and thin","volume":"114","author":"Linke","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2020.12.013_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2020.12.013_bib44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.kint.2020.12.013_bib45","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/bph.12468","article-title":"Targeting mitochondrial cardiolipin and the cytochrome c\/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis","volume":"171","author":"Birk","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2020.12.013_bib46","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.3390\/ijms20123094","article-title":"Mitochondria as a source and a target for uremic toxins","volume":"20","author":"Popkov","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2020.12.013_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lfs.2014.11.024","article-title":"N-Acetylcysteine as a potential strategy to attenuate the oxidative stress induced by uremic serum in the vascular system","volume":"121","author":"Rodrigues","year":"2015","journal-title":"Life Sci"},{"key":"10.1016\/j.kint.2020.12.013_bib48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jphs.2015.09.002","article-title":"Vascular nitric oxide: beyond eNOS","volume":"129","author":"Zhao","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.kint.2020.12.013_bib49","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3389\/fphys.2018.01648","article-title":"Mechanisms and modulation of oxidative\/nitrative stress in type 4 cardio-renal syndrome and renal sarcopenia","volume":"9","author":"Sarkozy","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.kint.2020.12.013_bib50","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1016\/j.febslet.2008.08.002","article-title":"Interrelations of mitochondrial fragmentation and cell death under ischemia\/reoxygenation and UV-irradiation: protective effects of SkQ1, lithium ions and insulin","volume":"582","author":"Plotnikov","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kint.2020.12.013_bib51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrn2417","article-title":"Mitochondrial fragmentation in neurodegeneration","volume":"9","author":"Knott","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.kint.2020.12.013_bib52","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.celrep.2018.05.054","article-title":"Redox regulation of mitochondrial fission protein Drp1 by protein disulfide isomerase limits endothelial senescence","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.kint.2020.12.013_bib53","first-page":"A15278","article-title":"Empagliflozin, a SGLT2 inhibitor, directly protects cardiomyocytes by off-target effect-mediated promotion of mitophagy [abstract]","volume":"140","author":"Maejima","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2020.12.013_bib54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","volume":"6","author":"Maejima","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.kint.2020.12.013_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/toxins9040114","article-title":"Inflammatory cytokines as uremic toxins: \u201cni son todos los que estan, ni estan todos los que son","volume":"9","author":"Castillo-Rodriguez","year":"2017","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.kint.2020.12.013_bib56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ndt\/gfx316","article-title":"Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1\/c-FOS-mediated induction of interleukin 6 expression","volume":"33","author":"Zickler","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.12.013_bib57","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1172\/JCI118175","article-title":"Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes","volume":"96","author":"Schmidt","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.12.013_bib58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/toxins11100578","article-title":"Endothelial toxicity of high glucose and its by-products in diabetic kidney disease","volume":"11","author":"Dou","year":"2019","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.kint.2020.12.013_bib59","doi-asserted-by":"crossref","first-page":"F645","DOI":"10.1152\/ajprenal.00398.2004","article-title":"Advanced glycation end products and the kidney","volume":"289","author":"Bohlender","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2020.12.013_bib60","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.kint.2020.12.013_bib61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/ATVBAHA.117.307263","article-title":"22016 ATVB Plenary Lecture: receptor for advanced glycation endproducts and implications for the pathogenesis and treatment of cardiometabolic disorders: spotlight on the macrophage","volume":"37","author":"Schmidt","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2020.12.013_bib62","first-page":"381","article-title":"Identification of a glucose sensor in the heart [abstract]","volume":"36","author":"Van Steenbergen","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2020.12.013_bib63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.kint.2020.12.013_bib64","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2020.12.013_bib65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","article-title":"Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress","volume":"109","author":"El-Daly","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.kint.2020.12.013_bib66","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1038\/s41598-019-42872-w","article-title":"The Na+\/H+-exchanger NHE1 regulates extra- and intracellular pH and nimodipine-sensitive [Ca2+]i in the suprachiasmatic nucleus","volume":"9","author":"Cheng","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2020.12.013_bib67","doi-asserted-by":"crossref","unstructured":"Chung YJ, Park KC, Tokar S, et\u00a0al. Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart [e-pub ahead of print]. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvaa1323. Accessed February 23, 2021.","DOI":"10.1093\/cvr\/cvaa323"},{"key":"10.1016\/j.kint.2020.12.013_bib68","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1161\/01.CIR.102.25.3032","article-title":"Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial","volume":"102","author":"Th\u00e9roux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2020.12.013_bib69","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","article-title":"Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula","volume":"5","author":"McAlister","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kint.2020.12.013_bib70","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/heartjnl-2019-315138","article-title":"Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?","volume":"105","author":"Radhakrishnan","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.kint.2020.12.013_bib71","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.ki.5000249","article-title":"Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging","volume":"69","author":"Mark","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.12.013_bib72","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2020.12.013_bib73","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2020.12.013_bib74","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ejhf.1486","article-title":"Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure","volume":"21","author":"Abraham","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2020.12.013_bib75","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1113\/JP274460","article-title":"In\u00a0vitro model to study the effects of matrix stiffening on Ca2+ handling and myofilament function in isolated adult rat cardiomyocytes","volume":"595","author":"van Deel","year":"2017","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.kint.2020.12.013_bib76","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/cvr\/cvy294","article-title":"Visualization and quantification of mitochondrial structure in the endothelium of intact arteries","volume":"115","author":"Durand","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kint.2020.12.013_bib77","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1096\/fj.11-196543","article-title":"Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer","volume":"26","author":"Rehman","year":"2012","journal-title":"FASEB J"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820315325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820315325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:58:08Z","timestamp":1758761888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820315325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0085253820315325"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.12.013","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin restores chronic kidney disease\u2013induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}